Price History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Trend
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Price Action
Support & Resistance Levels
Volume Analysis
Stop Loss Levels
Fixed Risk
Technical Levels
Moving Averages
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹1,415.1 Cr | ₹1,674.2 Cr | ₹1,569.6 Cr | ₹1,778.3 Cr |
| Net Profit | ₹92.3 Cr | ₹233.7 Cr | ₹163 Cr | ₹251.7 Cr |
| EPS | ₹1.71 | — | ₹3.02 | ₹4.67 |
| Operating Profit | ₹294.6 Cr | ₹469.8 Cr | ₹392.6 Cr | ₹486 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| Biocon Limited | ₹418.50 | +3.70% | 177.4 | ₹67.83K Cr mid Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 08 May 2026 | Interim Dividend - Rs 1.20 Per Share | INTERIM_DIVIDEND |
| 31 Oct 2025 | Interim Dividend - Re 0.80 Per Sh | INTERIM_DIVIDEND |
| 09 May 2025 | Interim Dividend - Rs 0.80 Per Share | INTERIM_DIVIDEND |
| 06 Nov 2024 | Interim Dividend - Rs 0.40 Per Share | INTERIM_DIVIDEND |
| 04 Jul 2024 | Annual General Meeting | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
| Date | Purpose | Type |
|---|---|---|
| 24 Jul 2026 | Financial Results | RESULTS |
Latest News
News for LAURUSLABS
View All
Laurus Labs zooms 53% in Q1FY27; logs sharpest quarterly rally in 5 years
Sustained clinical and commercial contracting across technologies and sites driving good growth outlook for CDMO business, the company said.
Aurobindo Pharma among 9 mid-cap stocks to hit 52-week highs & rally up to 20% in a month
The Sensex fell 372 points on Monday, but nine BSE Midcap stocks touched fresh 52-week highs, signalling resilient investor confidence. Bank of Maharashtra, Thermax, Bharat Forge, Oracle Financial Services and Laurus Labs were among the key outperformers despite broader market weakness.
Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improve
Laurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The company is investing ₹3,000 crore in expanding capacities, particularly for high-value CDMO services, which are projected to double their revenue share by 2030. Analysts are optimistic, raising earnings forecasts and maintaining a 'BUY' rating, anticipating continued growth across its diverse segments.